Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALADRE alpha-linolenic acid nanoformulation for pain treatment in sickle cell disease
PACTR202506834698530Phase 1Not yet recruiting
- Sponsor
- Saarland University
- Start
- Sep 2025
- Countries
- 1
01
Overview
Phase 1 trial in sickle cell disease (SCD) (4 arms), sponsored by Saarland University. Primary endpoints: Safety and tolerability, Vital signs and clinical safety assessments and 2 more. Planned start Sep 2025; status: not yet recruiting.
02
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on PACTR202506834698530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202506834698530.